Efficacy of Continuous Oral Administration of Lanthanum Carbonate over 24 months

Ishizu, Tomoko; Zhang, Hong; Matsunaga, Tsuneaki; Kaneko, Yoko; Taru, Yoshinori

doi:10.1111/1744-9987.12042

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of factors could be involved in these discrepancies, including characteristics of the patients, genetics, study design, sample size, and magnitude of changes in biochemical parameters. A self-controlled study by Ishizu et al 25 showed that after 40 hemodialysis patients continuously took lanthanum carbonate for 24 months, there was no significant difference in serum iPTH levels before and after treatment. In a study by Hutchison et al 7 , the dose of lanthanum carbonate was 375-2250 mg/day and serum iPTH levels decreased after 4 weeks.…”

Section: Characteristics Of the Patientsmentioning

confidence: 99%

Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia

Cui¹,

Jiang²,

Liu³

et al. 2022

Afr H. Sci.

View full text Add to dashboard Cite

Objective: This study aimed to examine whether a 12-week small-dose lanthanum carbonate (LaCO3; 500 mg/d) treatment could improve calcium and phosphorus metabolism and parathyroid function in Asian patients with end-stage renal disease (ESRD) under hemodialysis. Methods: This was a prospective observational study of patients treated at our Hospital between 10/2014 and 02/2015. The patients were given 500 mg/d of LaCO3 with lunch for 12 weeks. Results: Baseline and after 12-week treatment serum phosphorus levels were 2.49±0.51 mmol/L and 1.65±0.34 mmol/L (P<0.001). The baseline and after 12-week treatment calcium×phosphorus product were 69.40±17.34 mg2/dL2 and 44.27±9.67 mg2/dL2 (P<0.001). There was no significant difference in serum calcium and iPTH levels from baseline to after 12 weeks treatment (both P>0.05). Fourteen (25.9%) patients developed gastrointestinal adverse reactions to LaCO3and 10 patients improved after treatment. Conclusion: Far below the 1.5-3.0g/d required by the drug instructions, LaCO3 500 mg/d for 12 weeks can still reduce serum phosphorus level and calcium × phosphorus product, without serum calcium and iPTH levels increase. Keywords: Low dose; Lanthanum carbonate; Hyperphosphatemia; End-stage renal disease; Hemodialysis; Asian.

show abstract

Section: Characteristics Of the Patientsmentioning

confidence: 99%

Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia

Cui¹,

Jiang²,

Liu³

et al. 2022

Afr H. Sci.

View full text Add to dashboard Cite

show abstract

“…Sevelamer is more expensive compared to calcium-based phosphate binders [8]. The number of tablets is another obstacle for patient adherence [9].…”

Section: Introductionmentioning

confidence: 99%

Low Dose of Sevelamer is Enough to Prevent Coronary Artery Calcification Progression in Prevalent Hemodialysis Patients

Din¹

2016

OAJUN

View full text Add to dashboard Cite

Objective: Our objective is to study the possible role of low dose sevelamer hydrochloride on the rate of progression of coronary artery calcification among prevalent hemodialysis (HD) patients. Methods:Eighty HD patients were selected to this study. These patients were receiving oral calcium carbonate (CaCO3) as 200mg of elemental calcium with each meal (total of 1500 mg/day). They were randomized into two equal groups. The first group was administered sevelamer hydrochloride as 800 mg with each meal (2400 mg/day) instead of CaCO3 [Group I], while the oral CaCO3 was maintained as 200mg of elemental calcium with each meal in the 2 nd group [Group II]. Coronary artery calcification score (CCs) was assessed before stating and at the end of the trial. In addition, serum fibroblast growth factor 23 (FGF23), calcium, phosphorus, lipids and intact parathyroid hormone (PTH) were estimated in these two events. Results:The baseline CCs and serum FGF23 were comparable in the 2 groups (200 ± 98.45 vs. 198 ± 69.68 A and 4669.5 ± 3540.9 vs. 4737 ± 2578.2 pg/ml, P=0.75 and 0.34 for CCs and serum FGF23 in group I vs. group II respectively). On the other hand, CCs and serum FGF23 were significantly lower in group I compared to group II by the end of the trial (203 ± 97.95 vs. 292 ± 100.16 A and 3011.8 ± 1853.7 vs. 7071.5 ± 2650.4 pg/ml, p= 0.012 and <0.001 for CCs and serum FGF23 in group I vs. group II respectively). These significant changes were associated with a highly significant decrease of CaxP product after using sevelamer (53.7 ± 6.5 vs. 65.3 ± 5.55, in group I vs. group II respectively, p<0.001). CCS showed significant correlation with FGF 23 (r=0.634, p<0.001) but failed to show similar correlation with other studied parameters in both groups. Conclusion:Low dose Sevelamer HCL can withhold coronary artery calcification progression in prevalent HD patients, and significantly decreases FGF 23 level. These results may help to overcome the patient intolerance and economic burden of the full dose of sevelamer. Further studies comparing low dose versus full dose of sevelamer are needed in these patients

show abstract

Phosphate management in chronic kidney disease

Bhan

2014

Current Opinion in Nephrology and Hypertension

View full text Add to dashboard Cite

show abstract

Efficacy of Continuous Oral Administration of Lanthanum Carbonate over 24 months

Cited by 3 publications

References 5 publications

Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia

Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia

Low Dose of Sevelamer is Enough to Prevent Coronary Artery Calcification Progression in Prevalent Hemodialysis Patients

Phosphate management in chronic kidney disease

Contact Info

Product

Resources

About